| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
3 companies
Robert E Denham last filed a Form 4 in April 2021, as Director at NYT. The filings on record cover 3 companies. Robert E Denham's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
At the last filing, the largest reported position was 49,279 shares of CVX.
Robert E Denham has 36 Form 4 filings on record from February 2015 to April 2021, across 3 companies: Director at New York Times (NYT), 2016–2021; Director at Brookfield Oaktree (OAK-PA), 2015–2019; Director at Chevron (CVX), 2015–2017.
The 47 reported transactions were 34 stock awards, 6 option or other derivative awards, 4 option exercises and 2 open-market sales, plus smaller numbers of other types.
Counted by filing, the open-market trades come to no purchases and 2 sales worth about $177K.
The largest open-market sale was 3,492 shares of NYT at an average $27.84 on November 5, 2018, about $97K.
Shares as reported in the last Form 4 for each company; the most recent is from April 2021. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.